RPS6KA1 and breast carcinoma: Although the results obtained did not particularly confirm that the cell death observed after PCAIs treatment was led by RSK-induced apoptosis, at least by RSK3, we believe that treatment with RSK inhibitors and PCAIs has potential in the development of combination therapies for breast cancer.